Tucatinib/Tucatinib is an innovation from which company?

Tucatinib/Tucatinib, known as a new star in the anti-cancer field, is specially used to treat HER2-positive breast cancer. Its trade name is Tukysa, which is already known to many patients. This innovative drug was developed by Array BioPharma and further developed and promoted by Cascadian Therapeutics (formerly Oncothyreon and later part of Seattle Genetics).

In April 2020, this revolutionary drug received authoritative certification from the U.S. Food and Drug Administration (FDA), bringing new hope to patients with metastatic breast cancer who have failed to respond to traditional chemotherapy regimens. Tucatinib, with its unique mechanism, effectively curbs the spread of cancer cells by inhibiting the activity of HER2 protein.

As a tyrosine kinase inhibitor (TKI), tucatinib has demonstrated excellent efficacy in combination therapy with trastuzumab and capecitabine. Especially for patients with locally advanced or metastatic HER2-positive breast cancer, and even those whose cancer cells have spread to the brain, tucatinib has shown impressive therapeutic effects. These patients may have previously tried multiple treatment options such as trastuzumab, pertuzumab, and T-DM1.

The recommended usage of tucatinib is to take 300 mg orally daily divided into two doses to ensure the sustained effect of the drug in the body. Patients should continue taking tucatinib until their condition changes or the drug's side effects become intolerable.

However, despite the remarkable efficacy of tucatinib, patients should be aware of possible side effects when using it. Common side effects include diarrhea, vomiting, fatigue, and rash. Once these symptoms occur, patients should communicate with their doctor in time so that the treatment plan can be adjusted in time or necessary relief measures can be taken.